Laird Norton Wetherby Wealth Management
TCRT icon

Laird Norton Wetherby Wealth Management’s Alaunos Therapeutics TCRT Stock Holding History

Laird Norton Wetherby Wealth Management’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-69
Closed -$19K – 956
2021
Q3 		$19K Buy
+69
New +$21.1K ﹤0.01% 929

Other funds holding TCRT

MP
MSD Partners New York $76.8M AUM 34.91% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Discovery Capital Management
Discovery Capital Management South Norwalk, Connecticut $2.41B AUM 286.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Laird Norton Wetherby Wealth Management's TCRT Position: Q4 2021 in Review

Laird Norton Wetherby Wealth Management sold out of Alaunos Therapeutics (TCRT) in Q4 2021, closing a stake of 69 shares — an estimated $19K sold.

Laird Norton Wetherby Wealth Management first reported a position in TCRT in Q3 2021 and held it in 1 quarter. The position peaked at $19K in Q3 2021. 165 funds tracked by Wall St. Rank hold TCRT as of Q4 2021.

  • Laird Norton Wetherby Wealth Management reported no remaining Alaunos Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Laird Norton Wetherby Wealth Management sold 69 Alaunos Therapeutics shares in Q4 2021, an estimated $19K.
  • Laird Norton Wetherby Wealth Management first reported a position in Alaunos Therapeutics in Q3 2021 and held it in 1 quarter.
  • Laird Norton Wetherby Wealth Management's Alaunos Therapeutics position peaked at $19K in Q3 2021.
  • 165 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q4 2021.

Based on Laird Norton Wetherby Wealth Management's 13F filing for Q4 2021, filed 14 Feb 2022.